Clinical Trial Update: Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg 5 mg tablets vs reference product in healthy adults under fasting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg: 5 mg tablets (hydrochlorothiazide + amiloride hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension | Phase 1 | Status: COMPLETED | Results posted: 2018-08-31